Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 6.47B |
| Revenue (ttm) | 199.56M |
| Net Income (ttm) | 21.52M |
| Shares Out | 136.58M |
| EPS (ttm) | 0.15 |
| PE Ratio | 317.14 |
| Forward PE | 32.68 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $48.84 |
| Previous Close | $48.80 |
| Change ($) | 0.04 |
| Change (%) | 0.08% |
| Day's Open | 49.11 |
| Day's Range | 48.29 - 49.69 |
| Day's Volume | 207,034 |
| 52-Week Range | 13.90 - 49.69 |
SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) ap...
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of Perje...
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U...
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on th...
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration...
DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gi...
SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside...
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (C...
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food...
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneo...
The shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) are up 3.6% to trade at $32.77 at last check, after earlier hitting an all-time high of $33.23.
Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high. The...
Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreem...
SAN DIEGO, Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...
SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics: Enhanced Prospects, Expensive Valuations
A bull signal is flashing for Halozyme Therapeutics (HALO), which just came off a record peak
SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, t...
Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SAN DIEGO, June 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the u...
SAN DIEGO, June 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROME...
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, June 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen) market...
SAN DIEGO, May 28, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the fo...
Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 15th
SAN DIEGO, May, 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen...
Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2020 Results - Earnings Call Transcript
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...
About HALO
Halozyme Therapeutics operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administr... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Helen Torley | Employees 132 |
| Stock Exchange NASDAQ | Ticker Symbol HALO |
Financial Performance
In 2019, HALO's revenue was $195.99 million, an increase of 29.06% compared to the previous year's $151.86 million. Losses were -$72.24 million, -10.07% less than in 2018.
Analyst Forecasts
According to 12 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is 44.00, which is a decrease of -9.91% from the latest price.